NDA 213593 · Azurity
Konvomep
Omeprazole, Sodium Bicarbonate · Oral
Last checked: Nov 19, 2026Latest source record: Aug 30, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Aug 30, 2022
Approved uses
1
Original approval plus efficacy supplements
Registered trials
988
158 Phase 3, 48 recruiting
FAERS reports
699
301 serious, 37 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 16, 2025.
KONVOMEP is indicated in adults for: short-term treatment (4 to 8 weeks) of active benign gastric ulcer. reduction of risk of upper gastrointestinal (GI) bleeding in critically ill adult patients. KONVOMEP is a combination of omeprazole, a proton pump inhibitor (PPI) and sodium bicarbonate, indicated in adults for: •Treatment of active benign gastric ulcer ( 1 ) •Reduction of risk of upper gastrointestinal (GI) bleeding in critically ill patients ( 1 )
Mechanism: Omeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the gastric mucosa, omeprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production. This effect is dose related and leads to inhibition of both basal and stimulated acid secretion irrespective of the stimulus.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 30, 2022 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabelMedication Guide
1 products under this application
- KONVOMEP · OMEPRAZOLE 2MG/ML; SODIUM BICARBONATE 84MG/ML · FOR SUSPENSION, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Omeprazole" as an intervention, any sponsor and status, largest first.
- Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)Pivotal-lookingTerminated
Cogentus PharmaceuticalsIndustry
NCT00557921 · 5,000 participants (planned) · Start Dec 2007 · Primary completion Nov 2009
Drug: CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin; Plavix (clopidogrel 75 mg) and aspirin · For: Acute Coronary Syndrome; Myocardial Infarction; Coronary Artery Disease and 1 more
Sites: Alexander City, Alabama; Birmingham, Alabama; Geneva, Alabama · 491 sites in all
- Eradication of Helicobacter Pylori Subtypes at High Gastric Cancer Risk: a Cluster-randomized Controlled TrialPivotal-lookingNot yet recruiting
Fudan UniversityAcademic, hospital or other
NCT06943794 · 4,824 participants (planned) · Start Mar 30, 2026 · Primary completion May 1, 2030
Drug: recommendations for Hp eradication treatment · For: Gastric (Stomach) Cancer
Sites: Tongling, China
- Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With ArthritisPivotal-lookingCompleted
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT00141102 · 4,484 participants · Start Oct 2005 · Primary completion May 2009
Drug: Celecoxib; Diclofenac + Omeprazole · For: Osteoarthritis; Arthritis, Rheumatoid
Sites: Genk, Belgium; Ghent, Belgium; Hasselt, Belgium · 194 sites in all
- A Randomized Multi-Intervention Trial to Inhibit Precancerous Gastric Lesions in Lingu, Shandong ProvincePivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00339768 · 3,411 participants · Start Jul 1, 1995 · Primary completion Jun 10, 1996
Drug: Amoxicillin/omeprazole · For: Precancerous Gastric Lesions
Sites: Beijing, China
- Nexium (Esomeprazole) in Symptom Adapted Therapy in GERD PatientsPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00444275 · 3,029 participants · Start Mar 2007 · Primary completion Oct 2008
Drug: esomeprazole (Nexium®); Xolaam® · For: GERD
Sites: Rouen, France
- A Multi-center Study for Individual Treatment of Helicobacter Pylori InfectionPivotal-lookingStatus unknown
First Affiliated Hospital of Zhejiang UniversityAcademic, hospital or other
NCT02689583 · 3,000 participants (planned) · Start Mar 2016 · Primary completion Mar 2017
Drug: Antibiotic selection based on the antibiotic susceptibility testing · For: Gastritis; Gastric Ulcer
- Helicobacter Pylori Eradication to Prevent Gastric CancerPivotal-lookingActive, not recruiting
Jie-Jun WangAcademic, hospital or other
NCT01133951 · 3,000 participants · Start Jun 2010 · Primary completion Jan 2012
Drug: OAC triple therapy; Placebo · For: Helicobacter Infections; Stomach Neoplasms
Sites: Yangzhong, China
- A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's MetaplasiaPivotal-lookingCompleted
University of OxfordAcademic, hospital or other
NCT00357682 · 2,557 participants · Start Mar 10, 2005 · Primary completion May 31, 2017
Drug: Esomeprazole; Esomeprazole and 1 more · For: Esophageal Cancer; Precancerous Condition
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- chronic kidney disease108
- drug ineffective81
- acute kidney injury50
- renal failure44
- incorrect product administration duration41
- nausea34
- product use issue33
- headache29
- inappropriate schedule of product administration26
- death25
- off label use25
- diarrhoea24
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2010 | 3 |
| 2011 | 1 |
| 2014 | 2 |
| 2015 | 5 |
| 2016 | 12 |
| 2017 | 25 |
| 2018 | 62 |
| 2019 | 140 |
| 2020 | 106 |
| 2021 | 54 |
| 2022 | 54 |
| 2023 | 38 |
| 2024 | 75 |
| 2025 | 78 |
| 2026 | 43 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Konvomep (Omeprazole/Sodium Bicarbonate)
2024 spending
$4.5M
Beneficiaries
1,959
10,159 claims
Per beneficiary
$2,280
$1.41 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $1,917,158 |
| 2024 | $4,466,882 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Clopidogrel with or without omeprazole in coronary artery disease.
Bhatt DL, Cryer BL, Contant CF, et al. · N Engl J Med 2010 · Clinical Trial, Phase III, Multicenter Study
- Comparative effectiveness and tolerability of esomeprazole and omeprazole in gastro-esophageal reflux disease: A systematic review and meta-analysis.
Qi Q, Wang R, Liu L, et al. · Int J Clin Pharmacol Ther 2015 · Comparative Study, Meta-Analysis
- Curcuma longa Linn versus omeprazole in treatment of functional dyspepsia: A randomized, double-blind, placebo-controlled trial.
Yongwatana K, Harinwan K, Chirapongsathorn S, et al. · J Gastroenterol Hepatol 2022 · Randomized Controlled Trial
- Efficacy and Safety of Clopidogrel With and Without a Proton Pump Inhibitor: A Systematic Review and Meta-Analysis.
Axelsson MAB, Parodi López N, Wikström Jonsson E, et al. · Basic Clin Pharmacol Toxicol 2025 · Systematic Review, Meta-Analysis
- Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial.
Richter JE, Kahrilas PJ, Johanson J, et al. · Am J Gastroenterol 2001 · Clinical Trial, Comparative Study
- Omeprazole promotes proximal duodenal mucosal bicarbonate secretion in humans.
Mertz-Nielsen A, Hillingsø J, Bukhave K, et al. · Gut 1996 · Clinical Trial, Comparative Study
Sponsor: Azurity
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.